macroautophagy

AR7 is a retinoic acid receptor α (RARα) antagonist.

SLLN-15 is an orally active, selective, and potent enhancer of autophagy, activating cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1].

CA-5f is a potent late-stage macroautophagy/autophagy inhibitor that works by inhibiting autophagosome-lysosome fusion.

NEO214, an autophagy inhibitor and a covalent conjugate of the PDE4 inhibitor Rolipram and perillyl alcohol, exhibits anti-cancer activity and blood-brain barrier (BBB) permeability. It prevents autophagy-lysosome fusion, blocking autophagic flux and triggering glioma cell death via mTOR activation and TFEB (Transcription Factor EB) aggregation. NEO214 inhibition of Macroautophagy/autophagy in glioblastoma cells may overcome chemotherapy resistance in glioblastoma [1].